IBMS supports UK government’s strategy to control COVID-19

The national response to the COVID-19 pandemic has required an unprecedented increase in the UK’s capacity to provide timely and accurate testing for the SARS-CoV-2 virus. The Institute of Biomedical Science (IBMS) supports the UK government strategy to control the virus by increasing testing numbers and by implementing the test, track and trace programme.

However, the pace of upscaling testing capacity across the healthcare sector must not lead to a reduction in the quality of the diagnostic testing process. Before the set-up of more mass testing centres, it should work together to assure the quality of testing and the competence of staff and make sure that current and any future centres will be more closely integrated with National Health Service (NHS) systems.

Established diagnostic testing facilities (i.e. pathology laboratories in the NHS and private healthcare sector) have typically evolved their processes over a number of years and have some of the highest quality testing programmes in the world. This has been achieved through the implementation of robust quality management systems that are proven to provide high quality and safe services through medical laboratory accreditation (e.g. to ISO15189:2012 standards).

As the next phase of increasing testing capacity is undertaken, it is essential that the provision of high quality and safety testing service is at the centre of the national testing strategy. Quality for quantity should not be sacrificed.

Quality matters

It is well known in laboratory medicine that the one thing worse than no result is the wrong result. The IBMS expects that all testing facilities performing COVID-19 PCR and serology testing seek appropriate medical laboratory accreditation as soon as possible. There are now a number of laboratories that have achieved ISO15189 accreditation for their COVID-19 testing processes, and the number pending an assessment to grant this is increasing.

Laboratories that have medical laboratory accreditation are kite marked as providers of high quality and safe service, often for very similar tests to the COVID-19 assays. Prior accreditation provides reassurance that there is minimal risk of poor quality practise while a laboratory awaits accreditation for new tests. The IBMS recommends that all laboratories achieve accreditation as a mark of quality and assurance for patients.

High-quality staff deliver high-quality services

Statutory regulation. Due to the complexity of the testing being undertaken to detect the SARS-CoV-2 virus, there is a need for a highly skilled and regulated professional workforce. HCPC registration has been mandatory for a wide number of professions within healthcare for many years. The intention of registration is to:

  • Protect the public
  • Demonstrate skills and knowledge
  • Ensure service users are clear on the scope of practise registrants have and behaviours that should be expected
  • Provide a requirement for Continual Professional Development (CPD)
  • Maintain public confidence in the respective profession

The IBMS expects that any workforce undertaking diagnostic testing for COVID-19 should meet the same minimum requirements as any other medical laboratory workforce that is involved in diagnostic testing.

Non-registered staff. Non-registered staff contribute to the overall sample journey with a variety of roles. Data Entry and communications are performed by non-registered staff following standard operating procedures (SOPs). The level of technical roles non-registered staff perform varies with the level of automation in a laboratory’s process.

A significant level of benchwork can be performed by trained non-registered staff and that is common in NHS and independent sector environments alike. However, HCPC registered scientists must be available to provide ongoing indirect supervision and troubleshooting in this workflow model.

The ratio of Registered Scientists and non-registered support should be assessed in each individual situation; it will vary with the level of automation available and the stability of the assay and workflow, but should provide sufficient numbers of Registered Scientists that any supervision is real and not “nominal”.

The IBMS supports the development of non-HCPC registered scientists and support staff. Indirect supervision is a process that works well in medical laboratories and allows for an appropriate skill mix in the workplace. It has been widely accredited and meets ISO15189:2012 requirements if undertaken correctly. However, the IBMS would expect that the supervising HCPC registered scientist is only responsible for a number of unregistered staff that allows them to safely provide adequate supervision.

Scientific staff. The IBMS expects that all scientific staff supervising a laboratory section and/or group of non-registered staff working in the laboratory are HCPC registered as a biomedical scientist or clinical scientist with the appropriate experience and grade commensurate of the role in question.

The IBMS also strongly recommends that HCPC registered scientific staff should be the only staff group to undertake the following roles in the laboratory:

  • Review and interpretation of anomalous test results
  • Approval and subsequent technical authorisation of test results
  • Provide clinical authorisation and interpretation of test results*
  • Provide sign off for the validation or verification of new technologies, assays or equipment before being brought in to routine use
    *also to be provided by the General Medical Council (GMC) registered medical colleagues

Supporting the expertise of our members

The IBMS is proud of the expertise of our members who work at the heart of healthcare in laboratory medicine 24 hours a day, 365 days a year, contributing to over 70% of diagnoses in the NHS processing over a billion samples every year. The biomedical science workforce has continued to go above and beyond to get the UK into a position to deal with this pandemic and is working tirelessly to help get patients and their medical teams the results that they need.

The IBMS and our members want to ensure that all laboratory and rapid testing for COVID-19 is performed to the highest quality and in the safest manner possible. There is a welcome working with any institutions, government bodies or testing organisations to help support these objectives.


Image credit: Freepik